Alpha Teknova, Inc. (TKNO): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$6.34M
Year ended 2025-12-31
$6.34M
Trailing 12 months to 2026-06-30
+26.1%
3-year compound annual growth
+25.4%
5-year compound annual growth
$6.58M2020-12-31: $2.04M2021-12-31: $2.88M2022-12-31: $3.17M2023-12-31: $5.66M2024-12-31: $6.58M2025-12-31: $6.34M$6.34M
2020-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$6.34M-3.6%2026-03-02, From 2025-01-01
2024-12-31$6.58M+16.2%2026-03-02, From 2024-01-01
2023-12-31$5.66M+78.8%2025-03-07, From 2023-01-01
2022-12-31$3.17M+9.8%2024-03-27, From 2022-01-01
2021-12-31$2.88M+41.0%2023-03-30, From 2021-01-01
2020-12-31$2.04Mn/a2022-03-18, From 2020-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Alpha Teknova, Inc. (TKNO)2025-12-31$6.34M-3.6%
Immucell Corp (ICCC)2025-12-31$2.78M+2.0%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$9.77M-5.0%
Aspira Women's Health Inc. (AWHL)2025-12-31$112.0K+21.7%
Biomerica Inc (BMRA)2026-05-31$77.0K-11.5%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$2.19M+48.4%
Myriad Genetics Inc (MYGN)2025-12-31$53.70M-12.3%
Neogen Corp (NEOG)2026-05-31$116.30M-2.7%
Volitionrx Ltd (VNRX)2025-12-31$983.7K-11.6%

Compare TKNO, ICCC, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗